World Pharma News


AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca RSS Channel

Display # 
Title Published Date
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis 01 October 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline 11 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester 08 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack 04 September 2015
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab 01 September 2015
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial 24 August 2015
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments 07 August 2015
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer 05 August 2015
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases 03 August 2015
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa 27 July 2015

© World Pharma News 2006 - 2015

Top Desktop version